IL311480A - Reticuloclavin-3 variants and treatment of asthma with interleukin-4 alpha receptor antagonists - Google Patents

Reticuloclavin-3 variants and treatment of asthma with interleukin-4 alpha receptor antagonists

Info

Publication number
IL311480A
IL311480A IL311480A IL31148024A IL311480A IL 311480 A IL311480 A IL 311480A IL 311480 A IL311480 A IL 311480A IL 31148024 A IL31148024 A IL 31148024A IL 311480 A IL311480 A IL 311480A
Authority
IL
Israel
Prior art keywords
rcn3
reticulocalbin
il4r
interleukin
asthma
Prior art date
Application number
IL311480A
Other languages
English (en)
Hebrew (he)
Inventor
Charles Paulding
Shan Chen
Original Assignee
Regeneron Pharma
Charles Paulding
Shan Chen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Charles Paulding, Shan Chen filed Critical Regeneron Pharma
Publication of IL311480A publication Critical patent/IL311480A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6827Hybridisation assays for detection of mutation or polymorphism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL311480A 2021-09-30 2022-09-27 Reticuloclavin-3 variants and treatment of asthma with interleukin-4 alpha receptor antagonists IL311480A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163250546P 2021-09-30 2021-09-30
PCT/US2022/077088 WO2023056254A1 (en) 2021-09-30 2022-09-27 Reticulocalbin-3 (rcn3) variants and treatment of asthma with interleukin-4 receptor alpha (il4r) antagonists

Publications (1)

Publication Number Publication Date
IL311480A true IL311480A (en) 2024-05-01

Family

ID=83902767

Family Applications (1)

Application Number Title Priority Date Filing Date
IL311480A IL311480A (en) 2021-09-30 2022-09-27 Reticuloclavin-3 variants and treatment of asthma with interleukin-4 alpha receptor antagonists

Country Status (9)

Country Link
US (1) US20230151426A1 (https=)
EP (1) EP4409037A1 (https=)
JP (1) JP2024536001A (https=)
KR (1) KR20240067064A (https=)
CN (1) CN117957332A (https=)
CA (1) CA3230302A1 (https=)
IL (1) IL311480A (https=)
MX (1) MX2024003921A (https=)
WO (1) WO2023056254A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
WO2011156000A2 (en) * 2010-06-07 2011-12-15 Aerovance, Inc. Use of il-4/il-13 antagonists to treat eosinophilic disorders
AR098155A1 (es) * 2013-10-23 2016-05-04 Genentech Inc Métodos para diagnosticar y tratar trastornos eosinofílicos

Also Published As

Publication number Publication date
CN117957332A (zh) 2024-04-30
EP4409037A1 (en) 2024-08-07
KR20240067064A (ko) 2024-05-16
CA3230302A1 (en) 2023-04-06
JP2024536001A (ja) 2024-10-04
MX2024003921A (es) 2024-04-22
WO2023056254A1 (en) 2023-04-06
AU2022356375A1 (en) 2024-03-14
US20230151426A1 (en) 2023-05-18

Similar Documents

Publication Publication Date Title
IL314442A (en) Trinucleotide cap analogs and methods of using them
ZA202107515B (en) Liquid composition comprising antibody of human interleukin-4 receptor alpha
GB2617483B (en) Interleukin-18 variants and methods of use
JO2865B1 (en) Antibodies of high affinity for human interleukin-4 receptors
IL319779A (en) New bicyclic heterocyclic compounds and their uses
AU2003273300A8 (en) Modified glp-1 receptor agonists and their pharmacological methods of use
IL314922A (en) Targeted cytokines and methods of using them
IL284670A (en) A mixture of peptide ingredients for skin regeneration and healing and its use
EP4334706A4 (en) MULTIOMICS ANALYSIS DEVICE AND METHODS OF USE THEREOF
IL285730A (en) Compounds with proptosis-inducing activity and methods of using them
GB2615237B (en) Face shield with powered air purifying respirator and methods of use
SG11202109590VA (en) T cell receptors and methods of use thereof
IL311480A (en) Reticuloclavin-3 variants and treatment of asthma with interleukin-4 alpha receptor antagonists
GB2613900B (en) Novel compounds and methods of use thereof
HK40114684A (en) Reticulocalbin-3 (rcn3) variants and treatment of asthma with interleukin-4 receptor alpha (il4r) antagonists
GB0611154D0 (en) Novel receptor antagonists and their methods of use
IL299104A (en) Intracellular administration of a CEBP antagonist and methods of use
EP4110322A4 (en) SELECTIVE COVALENT ANDROGEN RECEPTOR ANTAGONISTS (SARCAS) AND METHODS OF USE THEREOF
IL313573A (en) Transgenic sirpα variants and methods of using them
IL290221A (en) T-cell receptors and methods for their use
IL311999A (en) New modulators of EHMT1 and EHMT2 and their therapeutic use
IL299654A (en) BRK peptides and methods of use
EP4259181A4 (en) INTERLEUKIN-17B RECEPTOR (IL-17RB) ANTAGONIST AND ITS USE
IL318954A (en) Recombinant interleukin-2-related receptors and methods of use
IL321736A (en) Engineered TGFβRII Variants and Methods for Using Them